...
首页> 外文期刊>Medicinal chemistry research: an international journal for rapid communications on design and mechanisms of action of biologically active agents >Synthesis, anticancer, anti-HIV-1, and antimicrobial activity of some tricyclic triazino and triazolo[4,3-e]purine derivatives
【24h】

Synthesis, anticancer, anti-HIV-1, and antimicrobial activity of some tricyclic triazino and triazolo[4,3-e]purine derivatives

机译:某些三环三嗪并三唑并[4,3-e]嘌呤衍生物的合成,抗癌,抗HIV-1和抗菌活性

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

In an effort to etablish new candidates with improved antineoplastic, anti-HIV-1 and antimicrobial activities, the synthesis of some new triazino and triazol-o[4,3-e]purine derivatives is described: 6,8-dimethyl-l, 4-dihydro-l ,2,4-triazino[4,3-e]purine-7,9(6H, 8H)-diones 3-6; 5,7,9-trimethyl-l,2,4-triazolo[4,3-e]purine-6,8(5H, 7H, 9H)-diones 11-13, together with the synthesis of the 8-substituted purine derivative: 8-(3,5-diamino-lH-pyrazol-4-yl)diazenyl-l,3-dimethyl-lH-purine-2,6(3H, 7H)-dione 7. The prepared compounds were tested for their in vitro anticancer, anti-HIV and antimicrobial activities. The results of the in vitro anticancer screening revealed that compound 3 exhibited considerable activity against melanoma MALME-3 M, non-small lung cancer HOP-92 and breast cancer T-47D (GI50 values of 25.2, 31.8, and 32.9 uM, respectively). The anti-HIV-1 results indicated that compounds 7 and 13c displayed moderate activity (maximum % cell protection 30.52 and 35.54 at 2 x 10~4 M, respectively). The in vitro antimicrobial data showed that compound 12 was the most active against P. aerugin-osa, it was equipotent to ampicillin (MIC < 100 ug/ml). While compound lid was the most active against P. vul-garis, it was as active as ampicillin (MIC < 50 u.g/ml). In addition, compounds 12 and 13c were the most active against S. aureus (MIC <50 and <25 |ig/ml, respectively). On the other hand, the tested compounds devoid of antifungal activity except 6b and lie which showed weak activity against A. niger.
机译:为了努力建立具有改进的抗肿瘤药,抗HIV-1和抗微生物活性的新候选药物,描述了一些新的三嗪并三唑-o [4,3-e]嘌呤衍生物的合成:6,8-二甲基-1, 4-二氢-1,2,4-三嗪[4,3-e]嘌呤-7,9(6H,8H)-二酮3-6; 5,7,9-三甲基-1,2,4-三唑并[4,3-e]嘌呤-6,8(5H,7H,9H)-二酮11-13,以及8-取代嘌呤的合成衍生物:8-(3,5-二氨基-1H-吡唑-4-基)二氮烯基-1,3-二甲基-1H-嘌呤-2,6(3H,7H)-二酮7。对制得的化合物进行了测试。体外抗癌,抗HIV和抗菌活性。体外抗癌筛选结果显示,化合物3对黑色素瘤MALME-3 M,非小细胞肺癌HOP-92和乳腺癌T-47D表现出相当大的活​​性(GI50值分别为25.2、31.8和32.9 uM)。 。抗HIV-1的结果表明化合物7和13c表现出中等活性(在2 x 10〜4 M时最大的细胞保护百分比分别为30.52和35.54)。体外抗菌数据表明,化合物12对铜绿假单胞菌活性最高,与氨苄西林等价(MIC <100 ug / ml)。复方盖对寻常型疟原虫的活性最高,但其活性与氨苄西林一样(MIC <50 u.g / ml)。此外,化合物12和13c对金黄色葡萄球菌的活性最高(分别为MIC <50和<25 | ig / ml)。另一方面,除了6b和11b以外,所测试的化合物没有抗真菌活性,它们对黑曲霉显示弱的活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号